Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue and EBIT exceeding estimates. In the wake of the Alvotech deal, we see a new investment case emerging—still overshadowed by the turbulence of the past year, the current market cap remains modest for a commercial-stage biotech company.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/